Fig. 2

The analytic framework: testing for UGT1A1 mutations in patients with metastatic colorectal cancer (CRC) treated with irinotecan (Camptosar). This schematic shows the analytic framework underlying the current review. The numbers indicate the four key questions contained in Table 1.